Neurocrine Biosciences (NBIX) Tops Q4 EPS by 2c ; Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall St set for higher open as Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mail
Get Alerts NBIX Hot Sheet
Price: $165.21 +0.22%
Financial Fact:
Deferred gain on real estate: 853K
Today's EPS Names:
ATS, SICP, FTCO, More
Financial Fact:
Deferred gain on real estate: 853K
Today's EPS Names:
ATS, SICP, FTCO, More
Join SI Premium – FREE
Neurocrine Biosciences (NASDAQ: NBIX) reported Q4 EPS of $1.88, $0.02 better than the analyst estimate of $1.86. Revenue for the quarter came in at $805.5 million versus the consensus estimate of $802.45 million.
GUIDANCE:
Neurocrine Biosciences sees FY2026 revenue of $2.7-2.8 billion, versus the consensus of $3.41 billion.
For earnings history and earnings-related data on Neurocrine Biosciences (NBIX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Bernstein SocGen on Neurocrine Bio. (NBIX): 'This latest Crenessity beat may serve as the positive inflection point'
- Grainger (GWW) Tops Q3 EPS by 87c ; Offers Guidance
- Seagate Technology shares drop amid sector selloff
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
